Natale Alessandra, Boeckmans Joost, Desmae Terry, De Boe Veerle, De Kock Joery, Vanhaecke Tamara, Rogiers Vera, Rodrigues Robim M
Department of In Vitro Toxicology & Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.
Department of In Vitro Toxicology & Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.
Toxicol Lett. 2018 Mar 1;284:184-194. doi: 10.1016/j.toxlet.2017.11.014. Epub 2017 Dec 15.
Phospholipidosis is a metabolic disorder characterized by intracellular accumulation of phospholipids. It can be caused by short-term or chronic exposure to cationic amphiphilic drugs (CADs). These compounds bind to phospholipids, leading to inhibition of their degradation and consequently to their accumulation in lysosomes. Drug-induced phospholipidosis (DIPL) is frequently at the basis of discontinuation of drug development and post-market drug withdrawal. Therefore, reliable human-relevant in vitro models must be developed to speed up the identification of compounds that are potential inducers of phospholipidosis. Here, hepatic cells derived from human skin (hSKP-HPC) were evaluated as an in vitro model for DIPL. These cells were exposed over time to amiodarone, a CAD known to induce phospholipidosis in humans. Transmission electron microscopy revealed the formation of the typical lamellar inclusions in the cell cytoplasm. Increase of phospholipids was already detected after 24 h exposure to amiodarone, whereas a significant increase of neutral lipid vesicles could be observed after 72 h. At the transcriptional level, the modulation of genes involved in DIPL was detected. These results provide a valuable indication of the applicability of hSKP-HPC for the quick assessment of drug-induced phospholipidosis in vitro, early in the drug development process.
磷脂沉积症是一种代谢紊乱疾病,其特征为细胞内磷脂蓄积。它可由短期或长期接触阳离子两亲性药物(CADs)引起。这些化合物与磷脂结合,导致其降解受到抑制,进而在溶酶体中蓄积。药物性磷脂沉积症(DIPL)常常是药物研发终止和上市后药物撤市的原因。因此,必须建立可靠的与人类相关的体外模型,以加速鉴定可能诱发磷脂沉积症的化合物。在此,对源自人类皮肤的肝细胞(hSKP - HPC)作为DIPL的体外模型进行了评估。这些细胞随时间暴露于胺碘酮,一种已知可在人类中诱发磷脂沉积症的CAD。透射电子显微镜显示在细胞质中形成了典型的层状包涵体。暴露于胺碘酮24小时后已检测到磷脂增加,而72小时后可观察到中性脂质小泡显著增加。在转录水平,检测到了参与DIPL的基因的调控。这些结果为hSKP - HPC在药物研发过程早期快速评估体外药物性磷脂沉积症的适用性提供了有价值的指示。